Saniona AB (publ) (STO:SANION)

Market Cap	907.71M
Revenue (ttm)	334.67M
Net Income (ttm)	188.71M
Shares Out	136.09M
EPS (ttm)	1.76
PE Ratio	3.79
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	301,809
Average Volume	662,804
Open	6.66
Previous Close	6.67
Day's Range	6.33 - 6.71
52-Week Range	1.74 - 9.91
Beta	0.86
RSI	48.64
Earnings Date	Apr 30, 2025

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, Germany, Denmark, the United Kingdom, and Mexico. It also develops medicines modulating ion channels. The company’s products include Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is Phase 2b clinical trial for the treatment of hypothalamic obesity and Pr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 22
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SANION